EUROPAC2 is an international, multicentre, randomised, phase III, double blind, placebo controlled, parallel group, outpatient study in patients aged 5-65 with Hereditary Pancreatitis and Idiopathic Chronic Pancreatitis. The trial will recruit 240 patients across three arms; Antox (vers)1.2 plus placebo MGCT, MGCT plus placebo Antox vers(1.2) or Placebo Antox (vers)1.2 plus placebo MGCT. UK sites are managed by the Liverpool Cancer Trials Unit and non-UK sites are managed by the co-ordinating centre in Greifswald, Germany
Admin/Site Area
Sorry there are currently no job vacancies
"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)
Read more Patient stories